ICAP

Early treatments for the drug-resistant disease required injections over many months, and the side effects, such as hearing loss, kidney failure, depression or psychosis, can be worse than the disease, says Dr. Wafaa El-Sadr, director of ICAP at Columbia University’s Mailman School of Public Health. But in the past decade, two drugs, bedaquiline and delaminid, have emerged to treat drug-resistant TB. “They’re taken by mouth and are well-tolerated,” she says. As the simpler, safer treatments become available, she says, they could be game changers for patients in the developing world.

Read more on the NPR website

Read more about ICAP’s work on TB and HIV

 

Related Items